PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-314.19%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
7.75%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
-313.81%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-286.19%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-286.19%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
6.89%
Share reduction more than 1.5x AVXL's 23.95%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
6.89%
Diluted share reduction more than 1.5x AVXL's 45.28%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
17.02%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
16.84%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14746.74%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-19558.18%
Negative 5Y OCF/share CAGR while AVXL is at 66.53%. Joel Greenblatt would question the firm’s operational model or cost structure.
-11613.56%
Negative 3Y OCF/share CAGR while AVXL stands at 81.15%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-30946.59%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-34054.52%
Negative 5Y net income/share CAGR while AVXL is 23.83%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-30407.41%
Negative 3Y CAGR while AVXL is 30.67%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-3646.86%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-832.34%
Negative 5Y equity/share growth while AVXL is at 43.26%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-628.80%
Negative 3Y equity/share growth while AVXL is at 46.13%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.36%
Asset growth well under 50% of AVXL's 11206.01%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-341.43%
We have a declining book value while AVXL shows 44.08%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-62.27%
Our R&D shrinks while AVXL invests at 149.26%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
43.14%
SG&A declining or stable vs. AVXL's 1486.81%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.